Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound methods
Aim. Evidence-backed execution summary for Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound methods from Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound.
Show snapshot details
On this page
This experiment, in seven questions
Jump straight to the part of the recipe you need. Data and provenance labels stay close to the action they support.
Shopping and prep list
What do I need before I start?
human
Subject model for the experiment.
- Use
- confirm full cohort details in the source paper
Methods
reagent used in the protocol.
- Use
- NIA/AA National Institute on Aging/Alzheimer's Association, AChEI acetyl-cholinesterase inhibitor, ASA American Society of Anesthesiologists
MRgFUS procedure
After completion of the sonication protocol, a gadolinium-enhanced T1 sequence was performed to verify definitive evidence of BBB opening. Contrast enhancement at the targeted region signified the end of the procedure. The patient was then taken out of the scanner, the stereotactic frame removed, and additional high...
- Use
- After completion of the sonication protocol, a gadolinium-enhanced T1 sequence was performed to verify definitive evidence of BBB opening. Contrast enhancement at the targeted region signified the end of the procedure. The patient was then taken out of the scanner, the stereotactic frame removed, and additional high...
Discussion
In this pilot study, we opened the BBB twice in the right frontal lobe, 1 month apart with the second volume twice the first. Because brains affected by AD are often atrophic, it was necessary to adjust the axial dimensions of the planned target so as to avoid sulci and blood vessels. Doing so underscored the import...
- Use
- In this pilot study, we opened the BBB twice in the right frontal lobe, 1 month apart with the second volume twice the first. Because brains affected by AD are often atrophic, it was necessary to adjust the axial dimensions of the planned target so as to avoid sulci and blood vessels. Doing so underscored the import...
MRgFUS procedure
A 3-Tesla MRI (Signa MR750; GE Healthcare, Milwaukee, Wis.) was used to obtain T1, T2 (fast spin echo), and T2* (gradient echo) weighted images for surgical planning. A region in the right frontal lobe was then selected for BBB opening. To minimize the risk, we avoided areas containing sulci and vessels within two c...
- Use
- A 3-Tesla MRI (Signa MR750; GE Healthcare, Milwaukee, Wis.) was used to obtain T1, T2 (fast spin echo), and T2* (gradient echo) weighted images for surgical planning. A region in the right frontal lobe was then selected for BBB opening. To minimize the risk, we avoided areas containing sulci and vessels within two c...
Before you run
What should be confirmed before execution?
First confirmation
Equipment is listed but no product mappings are linked.
Confirm before execution
This page is backed by a publishable Replication Data Ledger package with zero critical source-verification issues.
Confirm before execution
Open the source paper before finalizing run-specific details.
Procurement checkpoint
Use source-stated vendors where present. Treat mapped products as sourcing options unless the page marks an exact source match.
Open quote workflowStep-by-step procedure
What do I do, in order?
Introduction
Given the compelling preclinical evidence, we investigate for the first time the use of non-invasive MRgFUS to open the BBB in human patients, with mild-to-moderate, amyloid-positive AD. Our primary aim is to evaluate the clinical safety and technical feasibility of this procedure, and secondarily to measure the influence, if any, on clinical and beta-amyloid imaging markers of AD. We find that the BBB can be safely, temporarily, and repeatedly opened in an amyloid-rich brain region with a high degree of anatomic specificity.
Secondary outcome
For our secondary outcome, we did not detect a clinically significant change between 3 months and baseline, on tests of patient cognition or daily functioning. Table lists the clinical psychometric data at baseline and follow-up visits. Group PET changes in the regions of interest (ROIs) after stages 1 and 2 compared to baseline were -0.14 ± 0.22 (standard deviation, n = 5) and -0.08 ± 0.21 ( n = 4), respectively, which were not statistically significant ( p > 0.2, paired t -test, Fig., Supplementary Fig. -, Supplementary Tables, ). Fig. 3 [ 18 F]-Florbetaben uptake on PET before and after treatment. Standardized uptake value ratio images (SUVr) in the corresponding axial planes for [ 18 F]-Florbetaben PET scans at a baseline and b approximately 1 week after sonication...
Discussion
Efficient MRgFUS-mediated BBB opening is influenced by a number of procedural and technical variables. Determining the optimal power via a ramp test is the first step to achieving uniform BBB opening. Other factors include microbubble size and dose, volume and type of tissue targeted, microbubble handling, and coordination between sonication and microbubble injection. As with any procedure, additional experience will enhance its efficiency and success, and while we achieved successful BBB opening in all patients, results were most uniform in the last two patients (Supplementary Fig. ).
MRgFUS procedure
A 3-Tesla MRI (Signa MR750; GE Healthcare, Milwaukee, Wis.) was used to obtain T1, T2 (fast spin echo), and T2* (gradient echo) weighted images for surgical planning. A region in the right frontal lobe was then selected for BBB opening. To minimize the risk, we avoided areas containing sulci and vessels within two contiguous MRI slices in each of the axial, sagittal, and coronal planes. Once the target region was identified, patients received a weight-based intravenous injection of microbubble contrast (Definity®) (4 µl/kg), followed shortly by the application of low-frequency focused ultrasound to the target. MR thermometry was used to monitor tissue temperature at the sonicated region in real time. The sonication parameters were limited by the clinical device hardware and software, and corresponded to those previously tested in large animal models.
Outcomes
The primary outcomes were clinical and radiographic safety as well as technical feasibility of reversible and repeated BBB opening. Successful barrier opening and restoration was determined, respectively, by gadolinium leakage immediately after sonication and by the absence of enhancement 1 day after sonication at the target region on T1-weighted contrast images. Safety was measured by clinical exam during the procedure and at each follow-up, as well as radiographic examination for any adverse events, including hemorrhage, swelling, or mass effect. Follow-up visits were scheduled for 1 day, 1 week, and 1 month after each procedure, as well as 2 months following the second procedure (Fig. ). Adverse events were recorded and monitored in a prospective fashion.
[ 18 F]-Florbetaben PET CT image acquisition and analysis
PET CT scans to measure beta-amyloid deposition were performed at baseline and 1 week following each procedure. A transmission scan followed by a 20-min emission scan (four frame/5 min each) were acquired on the Phillips Gemini PET CT (3D mode) starting at 90 min after an 8 mCi ± 20% ( n = 14) radiotracer injection of [ 18 F]-florbetaben. The SUVr was calculated on a voxel-wise basis by dividing the summed PET images by the cerebellar gray matter ROI, consistent with other [ 18 F]-florbetaben studies. To derive the cerebellar gray matter ROI, the T1-weighted MR images were processed with the Freesurfer pipeline (version 5.1; http://surfer.nmr.mgh.harvard.edu/ ). The radioactivity in the cerebellar reference region was extracted after mapping the cerebellar gray matter ROI to the co-registered [ 18 F]-florbetaben scans. Image preprocessi...
Measurement outputs
What raw and processed outputs should exist?
The BBB was successfully opened in all patients who underwent the focused ultrasound procedure (Fig. and Supplementary Figure ). We primarily targeted white matter i...
- Raw artifact
- Per-sample or per-animal endpoint measurements collected during the experiment
- Processed artifact
- Structured table with cleaned measurements ready for comparison
- Reported as
- Summary statistics and between-group or across-timepoint comparisons
No patient experienced a serious adverse event during this study. There were no deaths, hemorrhages, swelling, or neurologic deficits on the day of procedure or during follow-up...
- Raw artifact
- Per-sample or per-animal endpoint measurements collected during the experiment
- Processed artifact
- Structured table with cleaned measurements ready for comparison
- Reported as
- Summary statistics and between-group or across-timepoint comparisons
For our secondary outcome, we did not detect a clinically significant change between 3 months and baseline, on tests of patient cognition or daily functioning. Table lists...
- Raw artifact
- Per-sample or per-animal endpoint measurements collected during the experiment
- Processed artifact
- Structured table with cleaned measurements ready for comparison
- Reported as
- Summary statistics and between-group or across-timepoint comparisons
Figure outlines the study design. Patients between age 50 and 85 with mild-to-moderate AD with an MMSE score equal to or greater than 18 were eligible for the study. Detai...
- Raw artifact
- Per-sample or per-animal endpoint measurements collected during the experiment
- Processed artifact
- Structured table with cleaned measurements ready for comparison
- Reported as
- Summary statistics and between-group or across-timepoint comparisons
Analysis plan
How should the outputs become interpretable results?
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
inferred from protocolPreprocessing / cleaning
The BBB was successfully opened in all patients who underwent the focused ultrasound procedure (Fig. and Supplementary Figure ).
from paperScoring or quantification
Quantify the primary readouts for this experiment: The BBB was successfully opened in all patients who underwent the focused ultrasound procedure (Fig. and Supplementary Figure ). We primarily targeted white matter i...; No patient experienced a serious adverse event during this study. There were no deaths, hemorrhages, swelling, or neurologic deficits on the day of procedure or during follow-up...; For our secondary outcome, we did not detect a clinically significant change between 3 months and baseline, on tests of patient cognition or daily functioning. Table lists...; Figure outlines the study design. Patients between age 50 and 85 with mild-to-moderate AD with an MMSE score equal to or greater than 18 were eligible for the study. Detai....
from paperStatistical comparison
The BBB was successfully opened in all patients who underwent the focused ultrasound procedure (Fig. and Supplementary Figure ). We primarily targeted white matter i...; For our secondary outcome, we did not detect a clinically significant change between 3 months and baseline, on tests of patient cognition or daily functioning. Table lists...; Figure outlines the study design. Patients between age 50 and 85 with mild-to-moderate AD with an MMSE score equal to or greater than 18 were eligible for the study. Detai...; PET CT scans to measure beta-amyloid deposition were performed at baseline and 1 week following each procedure. A transmission scan followed by a 20-min emission scan (four fram...
from paperReporting output
Report representative outputs alongside summary comparisons for The BBB was successfully opened in all patients who underwent the focused ultrasound procedure (Fig. and Supplementary Figure ). We primarily targeted white matter i..., No patient experienced a serious adverse event during this study. There were no deaths, hemorrhages, swelling, or neurologic deficits on the day of procedure or during follow-up..., For our secondary outcome, we did not detect a clinically significant change between 3 months and baseline, on tests of patient cognition or daily functioning. Table lists..., Figure outlines the study design. Patients between age 50 and 85 with mild-to-moderate AD with an MMSE score equal to or greater than 18 were eligible for the study. Detai....
inferred from protocolStructured statistical methods
The BBB was successfully opened in all patients who underwent the focused ultrasound procedure (Fig. and Supplementary Figure ). We primarily targeted white matter i...; For our secondary outcome, we did not detect a clinically significant change between 3 months and baseline, on tests of patient cognition or daily functioning. Table lists...; Figure outlines the study design. Patients between age 50 and 85 with mild-to-moderate AD with an MMSE score equal to or greater than 18 were eligible for the study. Detai...; PET CT scans to measure beta-amyloid deposition were performed at baseline and 1 week following each procedure. A transmission scan followed by a 20-min emission scan (four fram...
source structuredSource and audit
What supports the facts on this page?
Evidence quotes (6)
Given the compelling preclinical evidence, we investigate for the first time the use of non-invasive MRgFUS to open the BBB in human patients, with mild-to-moderate, amyloid-positive AD. Our primary aim is to evaluate the clinical safety and technical feasibility of this procedure, and secondarily to measure the influence, if any, on clinical and beta-amyloid imaging markers of AD. We find that the BBB can be safely, temporarily, and repeatedly opened in an amyloid-rich brain region with a high degree of anatomic specificity.
For our secondary outcome, we did not detect a clinically significant change between 3 months and baseline, on tests of patient cognition or daily functioning. Table lists the clinical psychometric data at baseline and follow-up visits. Group PET changes in the regions of interest (ROIs) after stages 1 and 2 compared to baseline were -0.14 ± 0.22 (standard deviation, n = 5) and -0.08 ± 0.21 ( n = 4), respectively, which were not statistically significant ( p > 0.2, paired t -test, Fig., Supplementary Fig. -, Supplementary Tables, ). Fig. 3 [ 18 F]-Florbetaben uptake on PET before and after treatment. Standardized uptake value ratio images (SUVr) in the corresponding axial planes for [ 18 F]-Florbetaben PET scans at a baseline and b approximately 1 week after sonication. c Gadolinium extravasation on T1-weighted MR images immediately after the blood-brain barrier disruption procedure demonstrates the targeted region
Efficient MRgFUS-mediated BBB opening is influenced by a number of procedural and technical variables. Determining the optimal power via a ramp test is the first step to achieving uniform BBB opening. Other factors include microbubble size and dose, volume and type of tissue targeted, microbubble handling, and coordination between sonication and microbubble injection. As with any procedure, additional experience will enhance its efficiency and success, and while we achieved successful BBB opening in all patients, results were most uniform in the last two patients (Supplementary Fig. ).
A 3-Tesla MRI (Signa MR750; GE Healthcare, Milwaukee, Wis.) was used to obtain T1, T2 (fast spin echo), and T2* (gradient echo) weighted images for surgical planning. A region in the right frontal lobe was then selected for BBB opening. To minimize the risk, we avoided areas containing sulci and vessels within two contiguous MRI slices in each of the axial, sagittal, and coronal planes. Once the target region was identified, patients received a weight-based intravenous injection of microbubble contrast (Definity®) (4 µl/kg), followed shortly by the application of low-frequency focused ultrasound to the target. MR thermometry was used to monitor tissue temperature at the sonicated region in real time. The sonication parameters were limited by the clinical device hardware and software, and corresponded to those previously tested in large animal models.
The primary outcomes were clinical and radiographic safety as well as technical feasibility of reversible and repeated BBB opening. Successful barrier opening and restoration was determined, respectively, by gadolinium leakage immediately after sonication and by the absence of enhancement 1 day after sonication at the target region on T1-weighted contrast images. Safety was measured by clinical exam during the procedure and at each follow-up, as well as radiographic examination for any adverse events, including hemorrhage, swelling, or mass effect. Follow-up visits were scheduled for 1 day, 1 week, and 1 month after each procedure, as well as 2 months following the second procedure (Fig. ). Adverse events were recorded and monitored in a prospective fashion.
PET CT scans to measure beta-amyloid deposition were performed at baseline and 1 week following each procedure. A transmission scan followed by a 20-min emission scan (four frame/5 min each) were acquired on the Phillips Gemini PET CT (3D mode) starting at 90 min after an 8 mCi ± 20% ( n = 14) radiotracer injection of [ 18 F]-florbetaben. The SUVr was calculated on a voxel-wise basis by dividing the summed PET images by the cerebellar gray matter ROI, consistent with other [ 18 F]-florbetaben studies. To derive the cerebellar gray matter ROI, the T1-weighted MR images were processed with the Freesurfer pipeline (version 5.1; http://surfer.nmr.mgh.harvard.edu/ ). The radioactivity in the cerebellar reference region was extracted after mapping the cerebellar gray matter ROI to the co-registered [ 18 F]-florbetaben scans. Image preprocessing was performed with statistical parametric mapping, version eight (SPM8, Institute of Neurology, London). PET-to-PET and MR-to-PET registrations were performed using the normalized mutual information algorithm, and images were spatially normalized into standard 3D space relative to the anterior co...
Machine-readable layer
[
{
"@context": "https://schema.org",
"@type": "HowTo",
"name": "Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound methods",
"description": "Evidence-backed execution summary for Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound methods from Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound.",
"totalTime": "PT5280M",
"step": [
{
"@type": "HowToStep",
"position": 1,
"name": "Introduction",
"text": "Given the compelling preclinical evidence, we investigate for the first time the use of non-invasive MRgFUS to open the BBB in human patients, with mild-to-moderate, amyloid-positive AD. Our primary aim is to evaluate the clinical safety and technical feasibility of this procedure, and secondarily to measure the influence, if any, on clinical and beta-amyloid imaging markers of AD. We find that the BBB can be safely, temporarily, and repeatedly opened in an amyloid-rich brain region with a high degree of anatomic specificity."
},
{
"@type": "HowToStep",
"position": 2,
"name": "Secondary outcome",
"text": "For our secondary outcome, we did not detect a clinically significant change between 3 months and baseline, on tests of patient cognition or daily functioning. Table lists the clinical psychometric data at baseline and follow-up visits. Group PET changes in the regions of interest (ROIs) after stages 1 and 2 compared to baseline were -0.14 ± 0.22 (standard deviation, n = 5) and -0.08 ± 0.21 ( n = 4), respectively, which were not statistically significant ( p > 0.2, paired t -test, Fig., Supplementary Fig. -, Supplementary Tables, ). Fig. 3 [ 18 F]-Florbetaben uptake on PET before and after treatment. Standardized uptake value ratio images (SUVr) in the corresponding axial planes for [ 18 F]-Florbetaben PET scans at a baseline and b approximately 1 week after sonication..."
},
{
"@type": "HowToStep",
"position": 3,
"name": "Discussion",
"text": "Efficient MRgFUS-mediated BBB opening is influenced by a number of procedural and technical variables. Determining the optimal power via a ramp test is the first step to achieving uniform BBB opening. Other factors include microbubble size and dose, volume and type of tissue targeted, microbubble handling, and coordination between sonication and microbubble injection. As with any procedure, additional experience will enhance its efficiency and success, and while we achieved successful BBB opening in all patients, results were most uniform in the last two patients (Supplementary Fig. )."
},
{
"@type": "HowToStep",
"position": 4,
"name": "MRgFUS procedure",
"text": "A 3-Tesla MRI (Signa MR750; GE Healthcare, Milwaukee, Wis.) was used to obtain T1, T2 (fast spin echo), and T2* (gradient echo) weighted images for surgical planning. A region in the right frontal lobe was then selected for BBB opening. To minimize the risk, we avoided areas containing sulci and vessels within two contiguous MRI slices in each of the axial, sagittal, and coronal planes. Once the target region was identified, patients received a weight-based intravenous injection of microbubble contrast (Definity®) (4 µl/kg), followed shortly by the application of low-frequency focused ultrasound to the target. MR thermometry was used to monitor tissue temperature at the sonicated region in real time. The sonication parameters were limited by the clinical device hardware and software, and corresponded to those previously tested in large animal models."
},
{
"@type": "HowToStep",
"position": 5,
"name": "Outcomes",
"text": "The primary outcomes were clinical and radiographic safety as well as technical feasibility of reversible and repeated BBB opening. Successful barrier opening and restoration was determined, respectively, by gadolinium leakage immediately after sonication and by the absence of enhancement 1 day after sonication at the target region on T1-weighted contrast images. Safety was measured by clinical exam during the procedure and at each follow-up, as well as radiographic examination for any adverse events, including hemorrhage, swelling, or mass effect. Follow-up visits were scheduled for 1 day, 1 week, and 1 month after each procedure, as well as 2 months following the second procedure (Fig. ). Adverse events were recorded and monitored in a prospective fashion."
},
{
"@type": "HowToStep",
"position": 6,
"name": "[ 18 F]-Florbetaben PET CT image acquisition and analysis",
"text": "PET CT scans to measure beta-amyloid deposition were performed at baseline and 1 week following each procedure. A transmission scan followed by a 20-min emission scan (four frame/5 min each) were acquired on the Phillips Gemini PET CT (3D mode) starting at 90 min after an 8 mCi ± 20% ( n = 14) radiotracer injection of [ 18 F]-florbetaben. The SUVr was calculated on a voxel-wise basis by dividing the summed PET images by the cerebellar gray matter ROI, consistent with other [ 18 F]-florbetaben studies. To derive the cerebellar gray matter ROI, the T1-weighted MR images were processed with the Freesurfer pipeline (version 5.1; http://surfer.nmr.mgh.harvard.edu/ ). The radioactivity in the cerebellar reference region was extracted after mapping the cerebellar gray matter ROI to the co-registered [ 18 F]-florbetaben scans. Image preprocessi..."
}
],
"tool": [
{
"@type": "HowToTool",
"name": "MRgFUS procedure"
},
{
"@type": "HowToTool",
"name": "Discussion"
},
{
"@type": "HowToTool",
"name": "MRgFUS procedure"
}
],
"supply": [
{
"@type": "HowToSupply",
"name": "Methods"
}
],
"isBasedOn": {
"@type": "ScholarlyArticle",
"headline": "Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound",
"datePublished": "2018",
"author": [
{
"@type": "Person",
"name": "Nir Lipsman"
},
{
"@type": "Person",
"name": "Ying Meng"
},
{
"@type": "Person",
"name": "Allison J. Bethune"
},
{
"@type": "Person",
"name": "Yuexi Huang"
},
{
"@type": "Person",
"name": "Benjamin Lam"
},
{
"@type": "Person",
"name": "Mario Masellis"
},
{
"@type": "Person",
"name": "Nathan Herrmann"
},
{
"@type": "Person",
"name": "Chinthaka Heyn"
},
{
"@type": "Person",
"name": "Isabelle Aubert"
},
{
"@type": "Person",
"name": "Alexandre Boutet"
},
{
"@type": "Person",
"name": "Gwenn S. Smith"
},
{
"@type": "Person",
"name": "Kullervo Hynynen"
},
{
"@type": "Person",
"name": "Sandra E. Black"
}
],
"identifier": "10.1038/s41467-018-04529-6"
}
},
{
"@context": "https://schema.org",
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Experiments",
"item": "https://replicatescience.com/experiments"
},
{
"@type": "ListItem",
"position": 2,
"name": "Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound methods",
"item": "https://replicatescience.com/experiments/blood-8211-brain-barrier-opening-in-alzheimer-s-disease-using-mr-guided-focused-ultrasound-methods-nir-lipsman-pmc6060168/blood-brain-barrier-opening-in-alzheimer-s-disease-using-mr-guided-focused-ultrasound-mlpha6m4"
}
]
}
]